• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc REGN

Last Price$358.00Day Change (%)2.62%
Open Price$349.00Day Change ($)9.13
Day Range348.43–359.8952-Week Range329.09–605.93

As of Fri 7/1/2016 3:56:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Health-care stocks rally as Medicare cost-cutting not triggered

    Health-care stocks rally as Medicare cost-cutting not triggered

  2. Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

    Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

  3. Global Hypercholesterolemia Pipeline Report 2016 - Therapeutics Review of 36 Companies & Drug Profile Activity - Research and Markets

    Global Hypercholesterolemia Pipeline Report 2016 - Therapeutics Review of 36 Companies & Drug Profile Activity - Research and Markets

  4. Stocks Slip Along With Oil -- Update

    Stocks Slip Along With Oil -- Update

  5. MARKET SNAPSHOT: Stocks Gather Steam As Investors Await Word From Yellen

    MARKET SNAPSHOT: Stocks Gather Steam As Investors Await Word From Yellen

  6. UPDATE: Stocks gather steam as investors await word from Yellen

    UPDATE: Stocks gather steam as investors await word from Yellen

  7. Sanofi, Regeneron: Phase 3 Trial for Dupilumab Show Positive Results

    Sanofi, Regeneron: Phase 3 Trial for Dupilumab Show Positive Results

  8. Wall Street stocks inch higher as investors wait for word from Fed's Yellen

    Wall Street stocks inch higher as investors wait for word from Fed's Yellen

  9. MARKET SNAPSHOT: Wall Street Stocks Inch Higher As Investors Wait For Word From Fed's Yellen

    MARKET SNAPSHOT: Wall Street Stocks Inch Higher As Investors Wait For Word From Fed's Yellen

  10. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016 - Research and Markets

    Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016 - Research and Markets

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.